Clinical Trial

A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1

Study acronym: CABNATE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-27.
Status change: Not Yet Recruiting → Recruiting 2026-05-15
Trial Details
NCT Number NCT07275606
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 44 participants
Start Date 2026-04-15
Primary Completion 2029-10-10 (estimated)
Study Completion 2029-10-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-19